Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.780
+0.170 (10.56%)
At close: Nov 6, 2026, 4:00 PM EST
1.780
0.00 (0.00%)
After-hours: Nov 6, 2026, 7:59 PM EST
Lexicon Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 183.2 | 34.33 | 66.66 | 22.47 | 46.35 | 64.07 |
Short-Term Investments | - | 61.9 | 171.3 | 147.56 | 92.01 | 22.68 |
Cash & Short-Term Investments | 183.2 | 96.23 | 237.96 | 170.03 | 138.36 | 86.74 |
Cash Growth | 58.00% | -59.56% | 39.95% | 22.89% | 59.50% | -43.04% |
Receivables | - | 2.38 | 3.47 | 1.01 | 0.03 | 0.01 |
Inventory | - | 0.28 | 0.23 | 0.38 | - | - |
Prepaid Expenses | - | 3 | 4.53 | 5.13 | 2.48 | 2.16 |
Total Current Assets | 183.2 | 101.9 | 246.19 | 176.55 | 140.87 | 88.92 |
Property, Plant & Equipment | 1.56 | 9.18 | 7.32 | 7.51 | 8.48 | 3.45 |
Goodwill | 44.54 | 44.54 | 44.54 | 44.54 | 44.54 | 44.54 |
Other Long-Term Assets | 12.72 | 29.37 | 0.37 | 0.83 | 0.41 | - |
Total Assets | 242.02 | 184.99 | 298.42 | 229.43 | 194.3 | 136.91 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | - | 3.08 | 14.8 | 14.39 | 10.4 | 9.15 |
Accrued Expenses | - | 11.55 | 29.27 | 15.87 | 11.49 | 11.88 |
Current Portion of Long-Term Debt | - | 4.6 | - | - | - | - |
Current Portion of Leases | - | 1.64 | 1.18 | 1.29 | 1.29 | 1.09 |
Total Current Liabilities | - | 20.87 | 45.25 | 31.55 | 23.17 | 22.12 |
Long-Term Debt | 51.89 | 49.41 | 100.3 | 99.51 | 48.58 | - |
Long-Term Leases | - | 6.59 | 4.6 | 5.27 | 5.42 | 1.19 |
Other Long-Term Liabilities | 26.28 | 0.58 | 2.32 | - | - | - |
Total Liabilities | 78.18 | 77.45 | 152.47 | 136.32 | 77.18 | 23.31 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 163.85 | 0.37 | 0.36 | 0.25 | 0.19 | 0.15 |
Additional Paid-In Capital | - | 2,130 | 2,117 | 1,863 | 1,709 | 1,609 |
Retained Earnings | - | -2,018 | -1,967 | -1,767 | -1,590 | -1,488 |
Treasury Stock | - | -5.19 | -4.62 | -2.89 | -2.06 | -7.52 |
Comprehensive Income & Other | - | 0.03 | 0.12 | 0.03 | -0.43 | -0.01 |
Shareholders' Equity | 163.85 | 107.54 | 145.95 | 93.11 | 117.12 | 113.6 |
Total Liabilities & Equity | 242.02 | 184.99 | 298.42 | 229.43 | 194.3 | 136.91 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 51.89 | 62.24 | 106.07 | 106.06 | 55.29 | 2.28 |
Net Cash (Debt) | 131.31 | 33.99 | 131.88 | 63.96 | 83.06 | 84.46 |
Net Cash Growth | 157.47% | -74.22% | 106.19% | -23.00% | -1.66% | -39.44% |
Net Cash Per Share | 0.32 | 0.09 | 0.41 | 0.29 | 0.50 | 0.58 |
Filing Date Shares Outstanding | 444.96 | 423.68 | 361.49 | 246.24 | 188.73 | 149.59 |
Total Common Shares Outstanding | 444.96 | 363.47 | 361.49 | 244.92 | 188.73 | 148.92 |
Working Capital | 183.2 | 81.03 | 200.95 | 145 | 117.69 | 66.8 |
Book Value Per Share | 0.37 | 0.30 | 0.40 | 0.38 | 0.62 | 0.76 |
Tangible Book Value | 119.3 | 63 | 101.41 | 48.57 | 72.58 | 69.05 |
Tangible Book Value Per Share | 0.27 | 0.17 | 0.28 | 0.20 | 0.38 | 0.46 |
Machinery | - | 2.39 | 2.39 | 4.35 | 4 | 4.72 |
Leasehold Improvements | - | 2.18 | 2.18 | 2.18 | 2.05 | 1.31 |